Trial Profile

A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 05 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Janssen Research & Development

Most Recent Events

28 Feb 2025 Planned End Date changed from 30 Apr 2026 to 31 Jan 2029.
02 Sep 2024 Recruitment End Date was found to be 31/12/2024
26 May 2023 Planned number of patients changed from 400 to 500.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com